You just read:

Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFRα D842V Mutant GIST and Fourth-Line GIST

News provided by

Blueprint Medicines Corporation

Jul 18, 2019, 16:01 ET